Publications by authors named "Ophir Borger"
Background: Premature adrenarche (PA) has been reported as a potential precursor of metabolic disease. We aimed to explore the interaction between body composition and cardiometabolic health of prepubertal children with PA.
Methods: This observational study comprised of 87 children with PA (15 boys, 8.
Background: There is a scarcity of published studies evaluating transgender/gender-diverse youth before initiating gender-affirming hormones.
Aim: To study the body composition, metabolic syndrome (MetS) components and lifestyle habits in treatment-naïve transgender youth.
Methods: Cross-sectional study evaluating 153 transgender youth [median age 15.
The objective of this study was to examine the association of designated sex at birth, body composition, and gender-affirming hormone treatment (GAHT) with the components of metabolic syndrome (MetS) (overweight/obesity, elevated blood pressure [BP], altered glucose metabolism, and dyslipidemia) in transgender/gender diverse (TGD) adolescents and young adults. TGD individuals underwent body composition studies by bioelectrical impedance analysis according to designated sex at birth, and their muscle-to-fat ratio (MFR) z-scores were calculated. Generalized estimating equations with binary logistic models ( = 326) were used to explore associations while adjusting for potential confounders.
View Article and Find Full Text PDFBackground: Advances in treatment could mitigate the expected adverse changes in the body composition of children and adolescents with type 1 diabetes (T1D).
Objectives: To examine the evolution of weight status and body composition and their association with glycaemic control and partial clinical remission in youth with T1D.
Methods: Ninety-nine participants with T1D (median age 9.
Article Synopsis
- The study explores the use of liraglutide, a GLP-1 analogue, as an off-label therapy for patients with rare genetic causes of early-onset obesity and related complications.
- Three case studies demonstrated that liraglutide can significantly halt weight gain, improve metabolic parameters, and support overall health in affected individuals despite their complex genetic backgrounds.
- The findings suggest that liraglutide may have broader benefits beyond weight loss, making it a potentially valuable treatment option for managing obesity-related conditions in genetically predisposed patients.